Loading quotes...
Forecast
The analysts' average price target is €116.88 (+9.23%). The median is €116.16 (+8.56%).
| Buy |
Â
12 |
| Hold |
Â
9 |
| Sell |
Â
0 |
News Go to news feed
Haemonetics strengthens partnership with CSL after rollout announcement and stronger quarterly results
Haemonetics benefits from CSL’s plasma decision to roll out NexSys‑PCS devices with Persona‑PLUS across all U.S. collection centers by the end of 2027, causing the stock to rise 17.5% to $119.47 on October 8. The company beat expectations last quarter with earnings per share of $1.14 and forecasts second‑quarter revenue of $345.1 million. The combination of a strong result and the expanded CSL partnership is likely to further support revenue growth and device sales. » More on finanzen.net
Haemonetics closes supply agreement with CSL Plasma and plans US rollout by end of 2027
Haemonetics has signed an extended supply agreement with major customer CSL Plasma, thereby reducing concentration risk in its blood plasma division. The company plans to equip all US plasma centers with NexSys-PCS devices and Persona-PLUS software by the end of 2027. The share reached a new yearly high of around $119 on sharply increased volume. » More on finanzen.net
Haemonetics brings AI strategy 89% gain after sale after twelve months
Investing.com placed Haemonetics in an AI-driven mid-cap strategy and exited on September 1 after 365 days at $103.07, representing a total return of 88.98%. Drivers of the rally were a non-exclusive supply agreement with CSL Plasma to roll out NexSys PCS devices, a better-than-expected quarter with improved EPS, and several analyst price-target increases. The position captured almost the entire price move and ranks among the largest realized gains in the most recent rebalancing. » More on de.investing.com
Financials
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | 297.88M | 8.62% |
| Gross profit | 178M | 8.73% |
| Net profit | 28.97M | 0.23% |
| EBITDA | 65.55M | 18.01% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €4.86B |
Number of shares | 45.5M |
52-week high/low | €110.59 - €43.78 |
| Dividends | No |
Beta | 0.54 |
P/E ratio | 58.08 |
PEG ratio | -1.55 |
P/B ratio | 6.48 |
P/S ratio | 4.03 |
Company profile
Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
| Name | Haemonetics Co. |
| CEO | Christopher A. Simon |
| Headquarters | Boston,
ma USA |
| Website | |
| Sector | Consumer Discretionary |
| Industry | Household Durables |
| IPO | 05/10/1991 |
| Employees | 3,009 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NYSE | HAE |
Frankfurt | HAZ.F |
DĂĽsseldorf | HAZ.DU |
MĂĽnchen | HAZ.MU |